Abstract:Melanoma is the most fatal skin cancer. In the early stages, it can be safely treated with surgery alone. However, since 2011, there has been an important revolution in the treatment of melanoma with new effective treatments. Targeted therapy and immunotherapy with checkpoint inhibitors have changed the history of this disease. To date, more than half of advanced melanoma patients are alive at 5 years; despite this breakthrough, approximately half of the patients still do not respond to treatment. For these reasons, new therapeutic strategies are required to expand the number of patients who can benefit from immunotherapy or combination with targeted therapy. Current research aims at preventing primary and acquired resistance, which are both responsible for treatment failure in about 50% of patients. This could increase the effectiveness of available drugs and allow for the evaluation of new combinations and new targets. The main pathways and molecules under study are the IDO inhibitor, TLR9 agonist, STING, LAG-3, TIM-3, HDAC inhibitors, pegylated IL-2 (NKTR-214), GITR, and adenosine pathway inhibitors, among others (there are currently about 3000 trials that are evaluating immunotherapeutic combinations in different tumors). Other promising strategies are cancer vaccines and oncolytic viruses. Another approach is to isolate and remove immune cells (DCs, T cells, and NK cells) from the patient's blood or tumor infiltrates, add specific gene fragments, expand them in culture with growth factors, and re-inoculate into the same patient. TILs, TCR gene transfer, and CAR-T therapy follow this approach. In this article, we give an overview over the current status of melanoma therapies, the clinical rationale for choosing treatments, and the new immunotherapy approaches.

Melanoma Management: From Epidemiology to Treatment and Latest Advances

How to Treat Melanoma? The Current Status of Innovative Nanotechnological Strategies and the Role of Minimally Invasive Approaches like PTT and PDT

Recent Advances in Nanotechnology for the Treatment of Melanoma

Melanoma treatment: from conventional to nanotechnology

Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma

Recent Advances in Targeted Nanoparticles Drug Delivery to Melanoma

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy

Cutaneous Melanoma: An Overview of Physiological and Therapeutic Aspects and Biotechnological Use of Serine Protease Inhibitors

Exploring Staging, Prognosis, and Treatment Innovations

Multifunctional Nanoparticle Approach for Targeting Melanoma

Advances in the Application of Nanomaterials to the Treatment of Melanoma

Targeted therapeutic strategies for melanoma

Advancements in Melanoma Therapies: From Surgery to Immunotherapy

Pathogenesis, Diagnosis, and Therapeutic Advances

Advances in Targeted Therapies and Combination Approaches for Melanoma: A Comprehensive Review

Metastatic melanoma – a review of current and future drugs

Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma

Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions

Advances in the discovery and development of melanoma drug therapies

Therapeutic options in cutaneous melanoma: latest developments